Amersham brachytherapy and Galil urology merge:
This article was originally published in Clinica
Executive Summary
Amersham has merged its non-core brachytherapy business with the urology operations of Galil Medical, a New York-based firm that has developed cryotherapy technology. The new US company, 75% owned by Amersham, is called Oncura, and will focus on minimally invasive prostate cancer treatment. As well as SeedNet cryotherapy products, it will supply RAPID Strand, OncoSeed, EchoSeed and TheraSeed brachytherapy seeds. Amersham's former president of the therapy business, John Jeans, is chairman, and James McGlone, ex-president of Galil Medical, is president and CEO.
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.